A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial

In previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), research is focused on developing fixed-duration strategies to improve long-term outcomes while sparing patients from serious toxicities. The ICLL-07 trial evaluated a fixed-duration (15-month) immunochemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Michallet, Anne-Sophie, Letestu, Rémi, Le Garff-Tavernier, Magali, Campos, Lydia, Ticchioni, Michel, Dilhuydy, Marie-Sarah, Morisset, Stephane, Rouille, Valérie, Mahé, Béatrice, Laribi, Kamel, Villemagne, Bruno, Ferrant, Emmanuelle, Tournilhac, Olivier, Delmer, Alain, Molina, Lysiane, Leblond, Véronique, Tomowiak, Cécile, de Guibert, Sophie, Orsini-Piocelle, Frederique, Banos, Anne, Carassou, Philippe, Cartron, Guillaume, Fornecker, Luc Mathieu, Ysebaert, Loic, Dartigeas, Caroline, Truchan-Graczyk, Margot, Vilque, Jean-Pierre, Schleinitz, Thérèse Aurran, Cymbalista, Florence, Leprêtre, Stéphane, Lévy, Vincent, Nguyen-Khac, Florence, Feugier, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410135/
https://www.ncbi.nlm.nih.gov/pubmed/37026799
http://dx.doi.org/10.1182/bloodadvances.2022009594

Ejemplares similares

Ejemplares similares